Document is current
Any future updates will be listed below
-
Authors
Wu, Fei
Kong, Yao
Chen, Wenjie
Liang, Dingfa
Xiao, Qin
Hu, Lijuan
Tan, Xiao
Wei, Jing
Liu, Yujuan
Deng, Xiaorong
Liu, Zhaoxia
Chen, Tingtao
-
Funding
Funding for this research was provided by:
the JiangXi Natural Science Foundation (20202ACBL206010, 20192ACBL20034)
The National Natural Science Foundation of China (82060638-tc)
Jiangxi Province "Double Thousand Talents Program" (Science and Technology Innovation High-level Talents Program)
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 14 March 2023
First Online: 22 March 2023
Declarations
:
: The animal study was approved by Ethical Committee of Nanchang Royo Biotech Co., Ltd (reference number RYE2019121702). All experiments were performed in accordance with relevant guidelines and regulations. The study is reported in accordance with ARRIVE guidelines (ExternalRef removed).The clinical experiment was approved by the Institutional Review Board (IRB) of the Second Affiliated Hospital of Nanchang University, registered in the Chinese Clinical Trial Registry (registration number: ChiCTR1900022522), which was conducted according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All participants in clinical experiment also provided a signed written informed consent.
: Not applicable.
: The study was conducted in the absence of any business or financial relationships that could be interpreted as potential conflicts of interest.
